His 2 year comment for ESS would be under an accel
Post# of 30028
Posted On: 01/20/2015 12:50:26 PM
His 2 year comment for ESS would be under an accelerated approval path. P2 will likely be finished and data by end of 2015 latest. Good data could result in submission to FDA and approval in 3-6 months. Data would have to be fantastic. It's one of those products where it would be hard for the FDA to justify hlosing it off the market for an additional 1-2 years because it can literally save lives due to a catastrophic event.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼